Elisabetta Carini

Via Stamira D'Ancona, 20
Milan, 20127, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 11 publications

Long-term outcome in a person with pandrug-resistant HIV: the added value of a multidisciplinary approach.

Long-term outcome in a person with pandrug-resistant HIV: the added value of a multidisciplinary approach.

Journal: JAC-antimicrobial resistance

Published: May 17, 2024

No need to modify treatment within the first month after rapid start of a tailored antiretroviral therapy: the TWODAY Study.

No need to modify treatment within the first month after rapid start of a tailored antiretroviral therapy: the TWODAY Study.

Journal: The new microbiologica

Published: May 29, 2023

Switching from a Non-Protease inhibitor-Based Regimen To the Fixed Dose Combination of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in Clinical Practice.

Switching from a Non-Protease inhibitor-Based Regimen To the Fixed Dose Combination of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in Clinical Practice.

Journal: Drug design, development and therapy

Published: January 18, 2022

Residual viremia in HIV-infected patients who continue a two-drug or switch to a three-drug integrase strand transfer inhibitor based regimen.

Residual viremia in HIV-infected patients who continue a two-drug or switch to a three-drug integrase strand transfer inhibitor based regimen.

Journal: AIDS (London, England)

Published: April 08, 2021

Analytical treatment interruption in chronic HIV-1 infection: time and magnitude of viral rebound in adults with 10 years of undetectable viral load and low HIV-DNA (APACHE study).

Analytical treatment interruption in chronic HIV-1 infection: time and magnitude of viral rebound in adults with 10 years of undetectable viral load and low HIV-DNA (APACHE study).

Journal: The Journal of antimicrobial chemotherapy

Published: December 08, 2018

An observational, retrospective analysis evaluating switching to raltegravir plus abacavir/lamivudine in HIV-1-infected patients: the ORASWIRAL study.

An observational, retrospective analysis evaluating switching to raltegravir plus abacavir/lamivudine in HIV-1-infected patients: the ORASWIRAL study.

Journal: Infectious diseases (London, England)

Published: September 12, 2017

Long-term efficacy and safety of rilpivirine plus abacavir and lamivudine in HIV-1 infected patients with undetectable viral load.

Long-term efficacy and safety of rilpivirine plus abacavir and lamivudine in HIV-1 infected patients with undetectable viral load.

Journal: PloS one

Published: May 19, 2017

Associations of statins and antiretroviral drugs with the onset of type 2 diabetes among HIV-1-infected patients.

Associations of statins and antiretroviral drugs with the onset of type 2 diabetes among HIV-1-infected patients.

Journal: BMC infectious diseases

Published: August 19, 2016

Unboosted atazanavir with lamivudine/emtricitabine for patients with long-lasting virological suppression.

Unboosted atazanavir with lamivudine/emtricitabine for patients with long-lasting virological suppression.

Journal: Journal of the International AIDS Society

Published: November 15, 2014

Simplification to atazanavir/ritonavir monotherapy for HIV-1 treated individuals on virological suppression: 48-week efficacy and safety results.

Simplification to atazanavir/ritonavir monotherapy for HIV-1 treated individuals on virological suppression: 48-week efficacy and safety results.

Journal: AIDS (London, England)

Published: July 25, 2014

Long-term glucose tolerance in highly experienced HIV-infected patients receiving nucleoside analogue-sparing regimens.

Long-term glucose tolerance in highly experienced HIV-infected patients receiving nucleoside analogue-sparing regimens.

Journal: AIDS (London, England)

Published: June 29, 2012

Showing 1-11 of 11

Last Updated: 09/26/2026